Automate Your Wheel Strategy on JNJ
With Tiblio's Option Bot, you can configure your own wheel strategy including JNJ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol JNJ
- Rev/Share 37.9433
- Book/Share 32.6431
- PB 5.7718
- Debt/Equity 0.0806
- CurrentRatio 1.0736
- ROIC 0.1293
- MktCap 453935290168.0
- FreeCF/Share 7.8498
- PFCF 23.8111
- PE 18.2162
- Debt/Assets 0.0331
- DivYield 0.027
- ROE 0.3269
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 4
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | JNJ | Daiwa Securities | Neutral | Outperform | -- | $203 | Oct. 20, 2025 |
| Upgrade | JNJ | Wells Fargo | Equal Weight | Overweight | -- | $212 | Oct. 3, 2025 |
| Upgrade | JNJ | Guggenheim | Neutral | Buy | -- | $206 | Sept. 23, 2025 |
| Upgrade | JNJ | Erste Group | Hold | Buy | -- | -- | July 23, 2025 |
| Downgrade | JNJ | Leerink Partners | Outperform | Market Perform | -- | $153 | May 13, 2025 |
| Resumed | JNJ | BofA Securities | -- | Neutral | -- | $166 | Dec. 10, 2024 |
News
Johnson & Johnson (JNJ) Presents at UBS Global Healthcare Conference 2025 Transcript
Published: November 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Johnson & Johnson ( JNJ ) UBS Global Healthcare Conference 2025 November 11, 2025 11:00 AM EST Company Participants Peter Menziuso Conference Call Participants Danielle Antalffy - UBS Investment Bank, Research Division Presentation Danielle Antalffy UBS Investment Bank, Research Division All right. Good morning, everyone.
Read More
Johnson & Johnson (JNJ) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript
Published: November 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Johnson & Johnson ( JNJ ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 11, 2025 10:30 AM EST Company Participants Sarah Brennan Mark Wildgust Conference Call Participants Vamil Divan - Guggenheim Securities, LLC, Research Division Presentation Vamil Divan Guggenheim Securities, LLC, Research Division Okay. I think we're ready to get going here.
Read More
Wall Street Analysts See Johnson & Johnson (JNJ) as a Buy: Should You Invest?
Published: November 11, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Read More
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting
Published: October 29, 2025 by: PRNewsWire
Sentiment: Neutral
The EPIC study will evaluate treatment with IMAAVY™ versus efgartigimod in adults with gMG and will include a treatment-switch arm The Company also announced new data from the pivotal Vibrance-MG study in which pediatric patients receiving treatment with IMAAVY™ demonstrated 72 weeks of sustained reduction in immunoglobulin G (IgG), sustained disease control and no new safety concerns IMAAVY™ is the only FcRn blocker for anti-AChR and anti-MuSK antibody positive adult and pediatric gMG patients aged 12 and older that has demonstrated sustained disease control SPRING HOUSE, Pa. , Oct. 29, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced …
Read More
J&J Stock Can Fall
Published: October 28, 2025 by: Forbes
Sentiment: Negative
Johnson & Johnson (JNJ) is currently encountering challenges. Even the largest corporations are not invulnerable.
Read More
Texas sues J&J and Kenvue, claiming they hid Tylenol's autism risks
Published: October 28, 2025 by: Reuters
Sentiment: Negative
The makers of Tylenol, Johnson & Johnson and Kenvue , were sued on Tuesday by Texas Attorney General Ken Paxton, who accused them of knowingly hiding the drug's links to autism and attention deficit hyperactivity disorder.
Read More
Here's Why Johnson & Johnson (JNJ) is a Strong Momentum Stock
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
JNJ vs. MRK: Which Blue-Chip Pharma Stock Should Be in Your Portfolio?
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Positive
J&J's diversified growth, strong pipeline, and robust balance sheet position it as a steadier long-term pick over Merck's Keytruda-dependent outlook.
Read More
Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies
Published: October 24, 2025 by: PRNewsWire
Sentiment: Neutral
Nipocalimab, a first-in-class FcRn blocker being investigated for SjD, met its primary endpoint in the Phase 2 DAHLIAS study with statistically significant improvement in ClinESSDAI score , which is based on 11 key systemic disease domains, at Week 24 versus placebo Critical patient-reported SjD symptoms including dryness, pain and fatigue trended towards greater improvement in the nipocalimab-treated group compared to placebo-treated patients Nipocalimab is the only investigational treatment to be granted Breakthrough Therapy Designation (BTD) by U.S. FDA for the treatment of adults living with moderate-to-severe SjD, and the Phase 3 DAFFODIL study is currently enrolling patients SPRING HOUSE, Pa. …
Read More
I have invested in dividends for 20 years. These stocks are my top dividend compounders of all time
Published: October 23, 2025 by: 24/7 Wall Street
Sentiment: Positive
In the world of investing, dividends have long been a popular way to earn income alongside growth opportunities with stocks.
Read More
Johnson & Johnson Stock To $134?
Published: October 22, 2025 by: Forbes
Sentiment: Negative
Our machine-driven multifactor analysis suggests it may be time to sell JNJ stock, as we hold a pessimistic outlook with a potential target price of $134. The company's Moderate operating performance and financial health, combined with its High valuation, make the stock appear Unattractive.
Read More
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Published: October 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Goldman Sachs Reveals Sectors With Top 2026 Payouts: 5 Strong Buys
Published: October 20, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Founded in 1869, Goldman Sachs is the world's second-largest investment bank by revenue and is ranked 55th on the Fortune 500 list of the largest United States corporations by total revenue.
Read More
Should You Buy, Sell or Hold J&J Stock After Robust Q3 Earnings?
Published: October 17, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ's strong Q3 results, upbeat sales outlook and expanding drug pipeline highlight resilience despite Stelara LOE.
Read More
J&J Bets on MedTech Growth With Orthopaedics Unit Spin-Off Plan
Published: October 16, 2025 by: Zacks Investment Research
Sentiment: Positive
J&J's surprise plan to spin off its Orthopaedics unit as DePuy Synthes is aimed at sharpening MedTech focus and boosting growth margins.
Read More
ETFs to Watch Post JNJ's Q3 Earnings Surprise & Bullish Outlook
Published: October 16, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ's Q3 earnings beat and raised 2025 sales outlook could lift healthcare ETFs like IHE, XLV and IYH, heavily weighted toward the drugmaker.
Read More
Johnson & Johnson's MedTech spin-off could boost focus, Bank of America says
Published: October 15, 2025 by: Proactive Investors
Sentiment: Positive
Bank of America maintained a ‘Neutral' rating on Johnson & Johnson (NYSE:JNJ) after the company posted third-quarter results slightly above expectations and hinted at a strategic MedTech shake-up. In a note Wednesday, the bank highlighted that J&J's third-quarter revenue and earnings per share beat consensus by roughly 1%, driven largely by stronger-than-expected performance from its Stelara biologic.
Read More
Johnson & Johnson Stock Can Keep Rising as Strategy Pays Off
Published: October 15, 2025 by: MarketBeat
Sentiment: Neutral
Johnson & Johnson's NYSE: JNJ stock price can continue to advance because its strategy to reinvigorate growth and widen margins is working. The plan centers on divesting underperforming healthcare businesses to focus on higher-margin, more potent growth markets.
Read More
JNJ Beats on Q3 Earnings, Ups Sales View, to Spin-off Orthopaedics Unit
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Positive
J&J tops Q3 forecasts, lifts 2025 sales outlook and plans to spin off its struggling Orthopaedics business.
Read More
Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Read More
Johnson & Johnson (JNJ) Q3 2025 Earnings Call Transcript
Published: October 14, 2025 by: Seeking Alpha
Sentiment: Neutral
Johnson & Johnson (NYSE:JNJ ) Q3 2025 Earnings Call October 14, 2025 8:30 AM EDT Company Participants Darren Snellgrove - Vice President of Investor Relations Joaquin Duato - CEO & Chairman Joseph Wolk - Executive VP & CFO Jennifer Taubert - Executive VP & Worldwide Chairman of Innovative Medicine Tim Schmid - Executive VP & Worldwide Chairman of MedTech John Reed - Executive Vice President of Innovative Medicine, R&D Conference Call Participants Alexandria Hammond - Wolfe Research, LLC Danielle Antalffy - UBS Investment Bank, Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Larry Biegelsen - Wells Fargo …
Read More
3 Dividend Aristocrats to Buy that Continued to Beat the Market
Published: October 14, 2025 by: 24/7 Wall Street
Sentiment: Positive
Finding top dividend stocks to invest in is one thing. Finding companies that can pay that dividend for years, and potentially decades, to come is a whole other story.
Read More
Compared to Estimates, Johnson & Johnson (JNJ) Q3 Earnings: A Look at Key Metrics
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Johnson & Johnson (JNJ) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Johnson & Johnson Stock Brushes Off Beat-and-Raise
Published: October 14, 2025 by: Schaeffers Research
Sentiment: Neutral
Johnson & Johnson (NYSE:JNJ) stock is down 1.2% to trade at $188.54 at last glance, brushing off an earnings and revenue beat for the third quarter.
Read More
Johnson & Johnson reports Q3 beat, plans orthopaedics spin-off
Published: October 14, 2025 by: Proactive Investors
Sentiment: Positive
Johnson & Johnson (NYSE:JNJ) posted third-quarter revenue and earnings that beat Wall Street estimates, driven by strength in its pharmaceuticals and medical devices businesses. The healthcare giant reported revenue of $23.99 billion for the quarter, up 6.8% from a year ago and slightly above analysts' expectations of $23.74 billion.
Read More
Is J&J's MedTech Segment Set for Another Quarter of Growth?
Published: October 13, 2025 by: Zacks Investment Research
Sentiment: Positive
J&J's MedTech sales are gaining traction in Cardiovascular, Surgery, and Vision, even as China???s VBP program continues to weigh on growth.
Read More
RTW Investments' Rod Wong: Expect more deals in biotech space
Published: October 10, 2025 by: CNBC Television
Sentiment: Positive
Rod Wong, RTW Investments CIO & Managing Director, joins CNBC's 'Money Movers' to discuss J&J's reported interest in buying Protagonist Therapeutics, whether he expects more consolidation in the sector, and much more.
Read More
Buying J&J Stock Ahead of Q3 Earnings? Here's What You Should Know
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Positive
J&J gears up for Q3 results with solid gains from Darzalex, Tremfya and MedTech, even as Stelara faces fierce biosimilar pressure.
Read More
About Johnson & Johnson (JNJ)
- IPO Date 1943-01-02
- Website https://www.jnj.com
- Industry Drug Manufacturers - General
- CEO Joaquin Duato
- Employees 138100